Aims: We evaluated the efficacy and safety of erlotinib, and patient characteristics affecting
progression-free survival (PFS), by analyzing data from two Phase II studies of first-line …

Abstract Background In Japan, the clinical efficacy of erlotinib monotherapy in epidermal
growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer was …

Introduction The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …

Objective Erlotinib has been reported to be useful for treatment of non-small-cell lung cancer
harboring mutation of the epidermal growth factor receptor gene EGFR-mt. However, no …

Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …

Background The purpose of this study was to evaluate the efficacy of erlotinib as front-line
treatment in clinically selected patients with non–small-cell lung cancer (NSCLC). Patients …

Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …

Introduction Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibition is the
preferred first-line treatment of advanced adenocarcinoma of the lung that harbors EGFR …

Backgrounds Efficacy of gefitinib therapy strongly depends on epidermal growth factor
receptor (EGFR)-mutation status in Asian patients with non-small cell lung cancer. Recently …

Importance Continuing molecularly targeted treatment beyond disease progression in non–
small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …